Life Sciences

Changes in Siegfried's Management Team

Wolfgang Wienand is stepping down as Chief Executive Officer of Siegfried and will join Lonza in summer 2024. The Board of Directors of Siegfried has appointed CFO Reto Suter as CEO ad interim. He will assume this additional responsibility as of May 1st, 2024. The search for the new Siegfried CEO has been initiated.

Wolfgang Wienand joined the Siegfried Group in August 2010 as Chief Scientific Officer and member of the Executive Committee. In December 2011, he took over the position of Chief Strategy Officer and was appointed CEO in January 2019.

Andreas Casutt, Chairman of the Board of Directors: “Wolfgang Wienand has made significant contributions to the continued success of our company over the past fourteen years. Together with his team, he has consistently positioned Siegfried strategically and operationally as a reliable, innovative partner of the global pharmaceutical industry. We deeply thank him for his major contributions to Siegfried’s great development!”

Reto Suter joined Siegfried in 2017 as Chief Financial Officer. Prior to that, he held various management positions in the industrial and financial sectors. He studied economics at the University of Zurich and the University of Washington in Seattle and holds a Doctorate in Banking and Finance.

Andreas Casutt: “Our Board of Directors is convinced that Reto Suter will successfully lead Siegfried together with our Executive Committee in the coming months thanks to his broad professional experience and proven track record as CFO. We have a stable, strong team, a clear strategy and we confirm our outlook for 2024 and for the coming years.”